Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Apr 16, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Apr 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, incorporation-by-reference
Related Tickers: IPHA
TL;DR
Innate Pharma filed a 6-K on 4/16/25, incorporating Exhibit 99.1.
AI Summary
Innate Pharma SA filed a Form 6-K on April 16, 2025, reporting information as of that date. The filing is for a foreign private issuer and indicates that the company files annual reports under Form 20-F. The document includes an incorporation by reference section for Exhibit 99.1, excluding certain promotional content.
Why It Matters
This filing provides routine updates for investors and regulatory bodies, ensuring transparency regarding the company's reporting status and incorporated documents.
Risk Assessment
Risk Level: low — This is a routine 6-K filing that primarily incorporates other documents and confirms reporting status, posing minimal new risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- April 16, 2025 (date) — Filing date
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
- Exhibit 99.1 (document) — Incorporated document
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information as a foreign private issuer and to incorporate Exhibit 99.1 by reference into the filing.
What is the filing date of this report?
The filing date of this report is April 16, 2025.
Does Innate Pharma file its annual reports under Form 20-F or Form 40-F?
Innate Pharma files its annual reports under cover of Form 20-F.
What specific content is excluded from the incorporation by reference of Exhibit 99.1?
The quotation from Jonathan Dickinson, Chief Executive Officer at Innate Pharma, the reference to the live webcast, and the related Internet and telephone links are excluded.
What is the principal executive office address of Innate Pharma?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 16, 2025 regarding Innate Pharma SA (IPHYF).